Department of Dermatology, Zealand University Hospital, Roskilde, Denmark.
Health Sciences Faculty, University of Copenhagen, Copenhagen, Denmark.
Br J Dermatol. 2018 Jul;179(1):182-185. doi: 10.1111/bjd.15769. Epub 2018 Mar 25.
An inappropriate immunological response to an unknown antigen has been suggested to play a role in the pathogenesis of hidradenitis suppurativa (HS). Studies have identified elevated levels of several proinflammatory cytokines, including interleukin (IL)-17A and tumour necrosis factor-α, nominating these as possible therapeutic targets. Secukinumab is an IL-17A monoclonal antibody, which binds to IL-17A and inhibits the cytokine interaction with the IL-17 receptors, inhibiting the inflammatory cascade. Here we report a case of a 47-year-old man, with Hurley stage III lesions on the neck, axillae, breasts, genital skin and buttocks, who had experienced only temporary benefit from different medical treatments over several years. After 12 weeks of treatment with secukinumab, the number of lesions reported by the patient within the period of the last 4 weeks was reduced from 23 to seven, his pain visual analogue scale (VAS) score was reduced from 5 to 3 and pain/utility/handicap VAS score was reduced from 7 to 4. These results may be taken to imply that IL-17 blockade could provide a possible therapeutic approach in the treatment of HS.
一种被认为在化脓性汗腺炎（HS）发病机制中起作用的对未知抗原的不适当免疫反应。研究已经确定了几种促炎细胞因子（包括白细胞介素（IL）-17A 和肿瘤坏死因子-α）的水平升高，将这些作为可能的治疗靶点。司库奇尤单抗是一种白细胞介素（IL）-17A 单克隆抗体，它与白细胞介素（IL）-17A 结合并抑制细胞因子与白细胞介素（IL）-17 受体的相互作用，从而抑制炎症级联反应。在这里，我们报告了一例 47 岁男性患者的病例，他的颈部、腋窝、乳房、生殖器皮肤和臀部有 Hurley III 期病变，多年来他仅从不同的药物治疗中获得暂时的缓解。在接受司库奇尤单抗治疗 12 周后，患者在过去 4 周内报告的病变数量从 23 个减少到 7 个，疼痛视觉模拟量表（VAS）评分从 5 分降至 3 分，疼痛/效用/障碍 VAS 评分从 7 分降至 4 分。这些结果可能表明 IL-17 阻断可能为 HS 的治疗提供一种潜在的治疗方法。
